Testimonials
Collated independently by Legal 500 research team.
‘Leadership of Creighton Macy directs the team on how they provide advice. Specifically, the team takes the time to understand the business and its inherent risks, and is thereby able to provide practical, commercial advice.’
‘Creighton Macy's leadership of his team has led to consistently excellent advice and outcomes. He is responsive, and detail-oriented while providing efficient and practical guidance.’
‘We have had the good fortune of working with Mark Hamer and his team at Baker McKenzie for several years. This team consistently adds value by finding creative solutions to often complex problems. They have meticulous attention to detail, but without being inefficient in any way. This team's intellect and experience are invaluable tools while navigating the complexities of the antitrust world. ’
‘Mark Hamer, Brian Burke, and Daniel Graulich are all extremely accessible and responsive. We are clearly not their largest client, yet we are treated as if we were, which is why this Baker McKenzie team is different than most other firms we engage on other matters (big and small). ’
‘The team is very knowledgeable and responsive. I feel like they put an emphasis on having teams of good people that are easy and enjoyable to work with.’
‘Creighton Macy is excellent and very easy to work with.’
‘The breadth of knowledge is impressive, even on esoteric items such as the formula for potential fines, considering the weight of a company's cooperation with the DOJ.’
‘Creighton Macy was always ready with an answer.'
Key clients
- Sika Corporation & Sika AG
- Numab Therapeutics
- PRADA USA
- Dolce & Gabbana
- Polo Ralph Lauren
- Environmental Data Resources
- International Franchise Association
- ALDI
- Chr. Hansen
- Rio Tinto
Work highlights
- Representing Sika in 19 private damages antitrust class actions now centralized as an MDL proceeding in the Southern District of New York, brought on behalf of direct and indirect purchaser classes.
- Advising Numab Therapeutics in the agreement with Johnson & Johnson to acquire Numab's subsidiary Yellow Jersey Therapeutics which holds its Phase 2-ready NM26 bispecific antibody program for atopic dermatitis for USD 1.25 billion.
- Advising PRADA in no-poach antitrust litigation in the Eastern District of New York (Brooklyn), Giordano, et al. v. Saks Fifth Avenue, et al.
Lawyers
Leading associates
Leading associates with regular involvement in their team's key work, and recognition from peers or clients as being ones to watch.
Practice head
Mark Hamer; Creighton Macy
Other key lawyers
Brian Burke; Jeffrey Martino; Ashley Eickhof; Daniel Graulich